Amisulpride

Last updated

Amisulpride
Amisulpride.svg
Amisulpride-xtal-1990-ball-and-stick-model.png
Clinical data
Trade names Solian, Barhemsys, others
Other namesAPD421
AHFS/Drugs.com Monograph
License data
Pregnancy
category
Routes of
administration 		By mouth, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 48% [5] [6]
Protein binding 16% [6]
Metabolism Liver (minimal; most excreted unchanged) [6]
Elimination half-life 12 hours [5]
Excretion Kidney [5] (23–46%), [7] [8] Faecal [6]
Identifiers
  • (RS)-4-amino-N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.068.916 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C17H27N3O4S
Molar mass 369.48 g·mol−1
3D model (JSmol)
  • O=S(=O)(c1cc(c(OC)cc1N)C(=O)NCC2N(CC)CCC2)CC
  • InChI=1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21) Yes check.svgY
  • Key:NTJOBXMMWNYJFB-UHFFFAOYSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Amisulpride is an antiemetic and antipsychotic medication used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; and at higher doses by mouth to treat schizophrenia and acute psychotic episodes. It is sold under the brand names Barhemsys [9] (as an antiemetic) and Solian, Socian, Deniban and others (as an antipsychotic). [6] At very low doses it is also used to treat dysthymia. [10]

Contents

It is usually classed with the atypical antipsychotics. Chemically it is a benzamide and like other benzamide antipsychotics, such as sulpiride, it is associated with a high risk of elevating blood levels of the lactation hormone, prolactin (thereby potentially causing the absence of the menstrual cycle, breast enlargement, even in males, breast milk secretion not related to breastfeeding, impaired fertility, impotence, breast pain, etc.), and a low risk, relative to the typical antipsychotics, of causing movement disorders. [11] [12] [13]

Amisulpride is indicated for use in the United States in adults for the prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class; and to treat PONV in those who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. [9]

Amisulpride is believed to work by blocking, or antagonizing, the dopamine D2 receptor, reducing its signalling. The effectiveness of amisulpride in treating dysthymia and the negative symptoms of schizophrenia is believed to stem from its blockade of the presynaptic dopamine D2 receptors. These presynaptic receptors regulate the release of dopamine into the synapse, so by blocking them amisulpride increases dopamine concentrations in the synapse. This increased dopamine concentration is theorized to act on dopamine D1 receptors to relieve depressive symptoms (in dysthymia) and the negative symptoms of schizophrenia. [10]

It was introduced by Sanofi-Aventis in the 1990s. Its patent expired by 2008, and generic formulations became available. [14] It is marketed in all English-speaking countries except for Canada. [13]

Medical uses

Schizophrenia

Although according to other studies it appears to have comparable efficacy to olanzapine in the treatment of schizophrenia, [15] amisulpride augmentation, similarly to sulpiride augmentation, has been considered a viable treatment option (although this is based on low-quality evidence) in clozapine-resistant cases of schizophrenia. [16] [17] Another recent study concluded that amisulpride is an appropriate first-line treatment for the management of acute psychosis. [18]

Postoperative nausea and vomiting

Amisulpride is indicated for use in the United States in adults for the prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class; and to treat PONV in those who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. [9]

Contraindications

Amisulpride's use is contraindicated in the following disease states and populations [6] [19] [11]

Neither is it recommended to use amisulpride in patients with hypersensitivities to amisulpride or the excipients found in its dosage form. [6]

Adverse effects

Very Common (≥10% incidence) [4]
Common (≥1%, <10% incidence) [4] [6] [20] [19] [11]
- constipation
- dry mouth
- disorder of accommodation
- Blurred vision
Rare (<1% incidence) [4] [6] [20] [19] [11]

Hyperprolactinaemia results from antagonism of the D2 receptors located on the lactotrophic cells found in the anterior pituitary gland. Amisulpride has a high propensity for elevating plasma prolactin levels as a result of its poor blood–brain barrier penetrability and hence the resulting greater ratio of peripheral D2 occupancy to central D2 occupancy. This means that to achieve the sufficient occupancy (~60–80% [21] ) of the central D2 receptors in order to elicit its therapeutic effects a dose must be given that is enough to saturate peripheral D2 receptors including those in the anterior pituitary. [22] [23]

Discontinuation

The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. [24] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. [25] Other symptoms may include restlessness, increased sweating, and trouble sleeping. [25] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. [25] Symptoms generally resolve after a short period of time. [25]

There is tentative evidence that discontinuation of antipsychotics can result in psychosis. [26] It may also result in reoccurrence of the condition that is being treated. [27] Rarely tardive dyskinesia can occur when the medication is stopped. [25]

Overdose

Torsades de pointes is common in overdose. [28] [29] Amisulpride is moderately dangerous in overdose (with the TCAs being very dangerous and the SSRIs being modestly dangerous). [30] [31]

Interactions

Amisulpride should not be used in conjunction with drugs that prolong the QT interval (such as citalopram, bupropion, clozapine, tricyclic antidepressants, sertindole, ziprasidone, etc.), [30] reduce heart rate and those that can induce hypokalaemia. Likewise it is imprudent to combine antipsychotics due to the additive risk for tardive dyskinesia and neuroleptic malignant syndrome. [30]

Pharmacology

Pharmacodynamics

Amisulpride [32] [33]
SiteKi (nM)SpeciesRef
SERT Tooltip Serotonin transporter>10,000Human [33]
NET Tooltip Norepinephrine transporter>10,000Human [33]
DAT Tooltip Dopamine transporter>10,000Human [33]
5-HT1A >10,000Human [33]
5-HT1B 1,744Human [33]
5-HT1D 1,341Human [33]
5-HT1E >10,000Human [33]
5-HT2A 8,304Human [33]
5-HT2B 13Human [33]
5-HT2C >10,000Human [33]
5-HT3 >10,000Human [33]
5-HT5A >10,000Human [33]
5-HT6 4,154Human [33]
5-HT7 11.5Human [33]
α1A >10,000Human [33]
α1B >10,000Human [33]
α1D >10,000Human [33]
α2A 1,114Human [33]
α2C 1,540Human [33]
β1 >10,000Human [33]
β2 >10,000Human [33]
β3 >10,000Human [33]
D1 >10,000Human [33]
D2 3.0Human [33]
D3 3.5Rat [33]
D4 2,369Human [33]
D5 >10,000Human [33]
H1 >10,000Human [33]
H2 >10,000Human [33]
H4 >10,000Human [33]
M1 >10,000Human [33]
M2 >10,000Human [33]
M3 >10,000Human [33]
M4 >10,000Human [33]
M5 >10,000Human [33]
σ1 >10,000Rat [33]
σ2 >10,000Rat [33]
MOR Tooltip μ-Opioid receptor>10,000Human [33]
DOR Tooltip δ-Opioid receptor>10,000Human [33]
KOR Tooltip κ-Opioid receptor>10,000Human [33]
GHBHigh Tooltip High-affinity γ-hydroxybutyric acid receptor50 (IC50 Tooltip Half-maximal inhibitory concentration)Rat [34]
NMDA
(PCP) 		>10,000Rat [35]
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site.

Amisulpride functions primarily as a dopamine D2 and D3 receptor antagonist. It has high affinity for these receptors with dissociation constants of 3.0 and 3.5 nM, respectively. [33] Although standard doses used to treat psychosis inhibit dopaminergic neurotransmission, low doses preferentially block inhibitory presynaptic autoreceptors. This results in a facilitation of dopamine activity, and for this reason, low-dose amisulpride has also been used to treat dysthymia. [6]

Amisulpride and its relatives sulpiride, levosulpiride, and sultopride have been shown to bind to the high-affinity GHB receptor at concentrations that are therapeutically relevant (IC50 Tooltip Half-maximal inhibitory concentration = 50 nM for amisulpride). [34]

Amisulpride, sultopride and sulpiride respectively present decreasing in vitro affinities for the D2 receptor (IC50 = 27, 120 and 181 nM) and the D3 receptor (IC50 = 3.6, 4.8 and 17.5 nM). [36]

Though it was long widely assumed that dopaminergic modulation is solely responsible for the respective antidepressant and antipsychotic properties of amisulpride, it was subsequently found that the drug also acts as a potent antagonist of the serotonin 5-HT7 receptor (Ki = 11.5 nM). [33] Several of the other atypical antipsychotics such as risperidone and ziprasidone are potent antagonists at the 5-HT7 receptor as well, and selective antagonists of the receptor show antidepressant properties themselves. To characterize the role of the 5-HT7 receptor in the antidepressant effects of amisulpride, a study prepared 5-HT7 receptor knockout mice. [33] The study found that in two widely used rodent models of depression, the tail suspension test, and the forced swim test, those mice did not exhibit an antidepressant response upon treatment with amisulpride. [33] These results suggest that 5-HT7 receptor antagonism mediates the antidepressant effects of amisulpride. [33]

Amisulpride also appears to bind with high affinity to the serotonin 5-HT2B receptor (Ki = 13 nM), where it acts as an antagonist. [33] The clinical implications of this, if any, are unclear. [33] In any case, there is no evidence that this action mediates any of the therapeutic effects of amisulpride. [33]

Amisulpride shows stereoselectivity in its actions. [37] Aramisulpride ((R)-amisulpride) has higher affinity for the 5-HT7 receptor (Ki = 47 nM vs. 1,900 nM) while esamisulpride ((S)-amisulpride) has higher affinity for the D2 receptor (4.0 nM vs. 140 nM). [37] [38] An 85:15 ratio of aramisulpride to esamisulpride (SEP-4199) which provides more balanced 5-HT7 and D2 receptor antagonism than racemic amisulpride (50:50 ratio of enantiomers) is under development for the treatment of bipolar depression. [39]

Through a high direct unmetabolized excretion, it has, despite its high usual dose, also high affinity for dopamine-D2-D3-receptors. Also the available literature gives us hints about also relatively high receptor dissociation kinetics (through a delayed but high occupancy at dopamine receptors after 6 hours from a 100 mg exposure). Moreover, this dopamine exposure could be slightly more "balanced" providing some little advantages over haloperidol in using it for drug exposure. Due to its lack of compensatory serotonin effects and also not having an anticholinergic profile, it may not considered as an effective alternative if akathasia is a problem. [5] [23] [40]

Society and culture

Brand names

Brand names include: Amazeo, Amipride (AU), Amival, Solian (AU, IE, RU, UK, ZA), Soltus, Sulpitac (IN), Sulprix (AU), Midora (RO) and Socian (BR). [41] [42]

Availability

Amisulpride is not approved by the Food and Drug Administration for use in the United States in psychiatric indications, but it is approved and in use throughout Europe, [42] Asia, Mexico, New Zealand and Australia [6] to treat psychosis and schizophrenia. [43] [44]

An IV formulation of Amisulpride was approved for the treatment of postoperative nausea and vomiting ("PONV") in the United States in February 2020. [45] [9] [46]

History of US clinical development

The U.S. Food and Drug Administration (FDA) approved a 10 mg/4mL amisulpride IV formulation for use in post-operative nausea based on evidence from four clinical trials of 2323 subjects undergoing surgery or experiencing nausea and vomiting after the surgery. [46] The trials were conducted at 80 sites in the United States, Canada and Europe. [46]

Two trials (Trials 1 and 2) enrolled subjects scheduled to have surgery. [46] Subjects were randomly assigned to receive either amisulpride or a placebo drug at the beginning of general anesthesia. [46] In Trial 1, subjects received amisulpride or placebo alone, and in Trial 2, they received amisulpride or placebo in combination with one medication approved for prevention of nausea and vomiting. [46] Neither the subjects nor the health care providers knew which treatment was being given until after the trial was complete. [46]

The trials counted the number of subjects who had no vomiting and did not use additional medications for nausea or vomiting in the first day (24 hours) after the surgery. [46] The results then compared amisulpride to placebo. [46]

The other two trials (Trials 3 and 4) enrolled subjects who were experiencing nausea and vomiting after surgery. [46] In Trial 3, subjects did not receive any medication to prevent nausea and vomiting before surgery and in Trial 4 they received the medication, but the treatment did not work. [46] In both trials, subjects were randomly assigned to receive either amisulpride or placebo. [46] Neither the subjects nor the health care providers knew which treatment was being given until after the trial was complete. [46]

The trials counted the number of subjects who had no vomiting and did not use additional medications for nausea or vomiting in the first day (24 hours) after the treatment. [46] The trial compared amisulpride to placebo. [46]

The FDA has not approved amisulpride for use in any psychiatric indication. LB Pharmaceuticals is developing N-methyl amisulpride for the use in the treatment of schizophrenia; a Phase 2 first-in-patient study is planned for 2023. [47]

See also

Related Research Articles

<span class="mw-page-title-main">Antipsychotic</span> Class of medications

Antipsychotics, previously known as neuroleptics and major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder. Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.

<span class="mw-page-title-main">Chlorpromazine</span> Antipsychotic medication

Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, severe behavioral problems in children including those with attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given orally, by intramuscular injection, or intravenously.

<span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

<span class="mw-page-title-main">Quetiapine</span> Atypical antipsychotic medication

Quetiapine, sold under the brand name Seroquel among others, is an atypical antipsychotic medication used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Despite being widely used as a sleep aid due to its sedating effect, the benefits of such use may not outweigh its undesirable side effects. It is taken orally.

<span class="mw-page-title-main">Olanzapine</span> Atypical antipsychotic medication

Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. It is also commonly used 'off-label' for treatment of chemotherapy induced nausea and vomiting (CINV) and as an appetite stimulant. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.

<span class="mw-page-title-main">Perphenazine</span> Antipsychotic medication

Perphenazine is a typical antipsychotic drug. Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.

<span class="mw-page-title-main">Aripiprazole</span> Atypical antipsychotic

Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. It is primarily used in the treatment of schizophrenia and bipolar disorder; other uses include as an add-on treatment in major depressive disorder and obsessive–compulsive disorder (OCD), tic disorders, and irritability associated with autism. Aripiprazole is taken by mouth or via injection into a muscle. A Cochrane review found low-quality evidence of effectiveness in treating schizophrenia.

<span class="mw-page-title-main">Dopamine antagonist</span> Drug which blocks dopamine receptors

A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia, bipolar disorder, and stimulant psychosis. Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting.

<span class="mw-page-title-main">Prochlorperazine</span> Medication for nausea, psychosis, and anxiety

Prochlorperazine, formerly sold under the brand name Compazine among others, is a medication used to treat nausea, migraines, schizophrenia, psychosis and anxiety. It is a less preferred medication for anxiety. It may be taken by mouth, rectally, injection into a vein, or injection into a muscle.

<span class="mw-page-title-main">Dopaminergic</span> Substance related to dopamine functions

Dopaminergic means "related to dopamine", a common neurotransmitter. Dopaminergic substances or actions increase dopamine-related activity in the brain.

<span class="mw-page-title-main">Sulpiride</span> Atypical antipsychotic

Sulpiride, sold under the brand name Dogmatil among others, is an atypical antipsychotic medication of the benzamide class which is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and is sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Asia, Central America, Europe, South Africa and South America. Levosulpiride is its purified levo-isomer and is sold in India for similar purposes. It is not approved in the United States, Canada, or Australia. The drug is chemically and clinically similar to amisulpride.

<span class="mw-page-title-main">Flupentixol</span> Typical antipsychotic drug of the thioxanthene class

Flupentixol (INN), also known as flupenthixol, marketed under brand names such as Depixol and Fluanxol is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1965 by Lundbeck. In addition to single drug preparations, it is also available as flupentixol/melitracen—a combination product containing both melitracen and flupentixol . Flupentixol is not approved for use in the United States. It is, however, approved for use in the UK, Australia, Canada, Russian Federation, South Africa, New Zealand, Philippines, Iran, Germany, and various other countries.

<span class="mw-page-title-main">Asenapine</span> Medication to treat schizophrenia

Asenapine, sold under the brand name Saphris among others, is an atypical antipsychotic medication used to treat schizophrenia and acute mania associated with bipolar disorder as well as the medium to long-term management of bipolar disorder.

<span class="mw-page-title-main">Melperone</span> Antipsychotic drug

Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It first entered clinical use in 1960s.

<span class="mw-page-title-main">Tiapride</span> Antipsychotic medication

Tiapride is a drug that selectively blocks D2 and D3 dopamine receptors in the brain. It is used to treat a variety of neurological and psychiatric disorders including dyskinesia, alcohol withdrawal syndrome, negative symptoms of psychosis, and agitation and aggression in the elderly. A derivative of benzamide, tiapride is chemically and functionally similar to other benzamide antipsychotics such as sulpiride and amisulpride known for their dopamine antagonist effects.

<span class="mw-page-title-main">Sultopride</span> Antipsychotic medication

Sultopride (trade names Barnetil, Barnotil, Topral) is an atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. Sultopride acts as a selective D2 and D3 receptor antagonist. It has also been shown to have clinically relevant affinity for the GHB receptor as well, a property it shares in common with amisulpride and sulpiride.

<span class="mw-page-title-main">Levosulpiride</span> Antipsychotic and prokinetic medication

Levosulpiride, sold under the brand name SULPEPTA , is a potent prokinetic agent of the benzamide class. It is a selective antagonist of the dopamine D2 receptors and 5-HT4 agonist on both central and peripheral nervous systems. Levosulpiride is claimed to have mood elevating properties.

<span class="mw-page-title-main">Desmethylclozapine</span> Active metabolite of the drug clozapine

N-Desmethylclozapine (NDMC), or norclozapine, is a major active metabolite of the atypical antipsychotic drug clozapine. Unlike clozapine, it possesses intrinsic activity at the D2/D3 receptors, and acts as a weak partial agonist at these sites similarly to aripiprazole and bifeprunox. Notably, NDMC has also been shown to act as a potent and efficacious agonist at the M1 and δ-opioid receptors, unlike clozapine as well. It was hypothesized that on account of these unique actions, NDMC might underlie the clinical superiority of clozapine over other antipsychotics. However, clinical trials found NMDC itself ineffective in the treatment of schizophrenia. This may be because it possesses relatively low D2/D3 occupancy compared to 5-HT2 (<15% versus 64–79% at a dose of 10–60 mg/kg s.c. in animal studies). Albeit not useful in the treatment of positive symptoms on its own, it cannot be ruled out that NDMC may contribute to the efficacy of clozapine on cognitive and/or negative symptoms.

<span class="mw-page-title-main">Clocapramine</span> Antipsychotic medication

Clocapramine, also known as 3-chlorocarpipramine, is an atypical antipsychotic of the iminostilbene class which was introduced in Japan in 1974 by Yoshitomi for the treatment of schizophrenia. In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic.

<span class="mw-page-title-main">Aripiprazole lauroxil</span> Chemical compound

Aripiprazole lauroxil, sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes. It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia. Aripiprazole lauroxil was approved by the U.S. Food and Drug Administration (FDA) on 5 October 2015.

References

  1. ↑ "Australian Product Information – Solian (Amisulpride) Tablets And Solution". TGA eBS. Retrieved 10 May 2020.
  2. ↑ "Amisulpride (Barhemsys) Use During Pregnancy". Drugs.com. 2 September 2020. Retrieved 24 September 2020.
  3. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  4. 1 2 3 4 "Amisulpride 100 mg Tablets - Summary of Product Characteristics (SmPC)". (emc). 5 July 2019. Archived from the original on 26 February 2020. Retrieved 26 February 2020.
  5. 1 2 3 4 Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G (January 2002). "A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers". Human Psychopharmacology. 17 (1): 1–13. doi:10.1002/hup.320. PMID   12404702. S2CID   23877366.
  6. 1 2 3 4 5 6 7 8 9 10 11 "Solian tablets and solution product information" (PDF). TGA eBusiness Services. Sanofi-Aventis Australia Pty Ltd. 27 September 2019. Retrieved 26 February 2020.
  7. ↑ Caccia S (May 2000). "Biotransformation of post-clozapine antipsychotics: pharmacological implications". Clinical Pharmacokinetics. 38 (5): 393–414. doi:10.2165/00003088-200038050-00002. PMID   10843459. S2CID   68853079.
  8. ↑ Noble S, Benfield P (December 1999). "Amisulpride: A Review of its Clinical Potential in Dysthymia". CNS Drugs. 12 (6): 471–483. doi:10.2165/00023210-199912060-00005. S2CID   71691764.
  9. 1 2 3 4 "Barhemsys (amisulpride) injection, for intravenous use" (PDF). U.S. Food and Drug Administration (FDA). February 2020. Retrieved 26 February 2020.
  10. 1 2 Pani L, Gessa GL (2002). "The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia". Molecular Psychiatry. 7 (3): 247–253. doi: 10.1038/sj.mp.4001040 . PMID   11920152.
  11. 1 2 3 4 Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.
  12. 1 2 3 Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–962. doi:10.1016/S0140-6736(13)60733-3. PMID   23810019. S2CID   32085212.
  13. 1 2 Brayfield A, ed. (June 2017). "Amisulpride: Martindale: The Complete Drug Reference". MedicineComplete. Pharmaceutical Press. Retrieved 5 August 2017.
  14. ↑ De Silva V, Hanwella R (April 2008). "Pharmaceutical patents and the quality of mental healthcare in low- and middle-income countries". The Psychiatrist. 32 (4): 121–23. doi: 10.1192/pb.bp.107.015651 .
  15. ↑ Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, et al. (January 2010). "Amisulpride versus other atypical antipsychotics for schizophrenia". The Cochrane Database of Systematic Reviews. 2013 (1): CD006624. doi:10.1002/14651858.CD006624.pub2. PMC   4164462 . PMID   20091599.
  16. ↑ Solanki RK, Singh P, Munshi D (October–December 2009). "Current perspectives in the treatment of resistant schizophrenia". Indian Journal of Psychiatry. 51 (4): 254–260. doi: 10.4103/0019-5545.58289 . PMC   2802371 . PMID   20048449.
  17. ↑ Mouaffak F, Tranulis C, Gourevitch R, Poirier MF, Douki S, Olié JP, et al. (2006). "Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia". Clinical Neuropharmacology. 29 (1): 28–33. doi:10.1097/00002826-200601000-00009. PMID   16518132. S2CID   29682562.
  18. ↑ Nuss P, Hummer M, Tessier C (March 2007). "The use of amisulpride in the treatment of acute psychosis". Therapeutics and Clinical Risk Management. 3 (1): 3–11. doi: 10.2147/tcrm.2007.3.1.3 . PMC   1936283 . PMID   18360610.
  19. 1 2 3 Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN   978-0-85711-084-8.
  20. 1 2 Truven Health Analytics, Inc. DRUGDEX System (Internet) [cited 2013 Sep 19]. Greenwood Village, CO: Thomsen Healthcare; 2013.
  21. ↑ Brunton L, Chabner B, Knollman B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN   978-0-07-162442-8.
  22. ↑ McKeage K, Plosker GL (2004). "Amisulpride: a review of its use in the management of schizophrenia". CNS Drugs. 18 (13): 933–956. doi:10.2165/00023210-200418130-00007. PMID   15521794. S2CID   9054960.
  23. 1 2 Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S (October 2008). "Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine". Schizophrenia Research. 105 (1–3): 224–235. doi:10.1016/j.schres.2008.07.005. PMID   18710798. S2CID   11315672.
  24. ↑ Joint Formulary Committee, ed. (March 2009). "4.2.1". British National Formulary (57 ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p. 192. ISBN   978-0-85369-845-6. Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
  25. 1 2 3 4 5 Haddad PM, Dursun S, Deakin B (2004). Adverse Syndromes and Psychiatric Drugs: A Clinical Guide. OUP Oxford. pp. 207–216. ISBN   978-0-19-852748-0.
  26. ↑ Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse". Acta Psychiatrica Scandinavica. 114 (1): 3–13. doi:10.1111/j.1600-0447.2006.00787.x. PMID   16774655. S2CID   6267180.
  27. ↑ Sacchetti E, Vita A, Siracusano A, Fleischhacker W (2013). Adherence to Antipsychotics in Schizophrenia. Springer Science & Business Media. p. 85. ISBN   978-8-84-702679-7.
  28. ↑ Isbister GK, Balit CR, Macleod D, Duffull SB (August 2010). "Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes". Journal of Clinical Psychopharmacology. 30 (4): 391–395. doi:10.1097/JCP.0b013e3181e5c14c. PMID   20531221. S2CID   205710487.
  29. ↑ Joy JP, Coulter CV, Duffull SB, Isbister GK (August 2011). "Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses". Clinical Pharmacology and Therapeutics. 90 (2): 243–245. doi:10.1038/clpt.2011.107. PMID   21716272. S2CID   26412012.
  30. 1 2 3 Taylor D, Paton C, Shitij K (2012). Maudsley Prescribing Guidelines in Psychiatry (11th ed.). West Sussex: Wiley-Blackwell. ISBN   978-0-47-097948-8.
  31. ↑ Levine M, Ruha AM (July 2012). "Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management". CNS Drugs. 26 (7): 601–611. doi:10.2165/11631640-000000000-00000. PMID   22668123. S2CID   24628641.
  32. ↑ Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  33. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (July 2009). "Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo". Psychopharmacology. 205 (1): 119–128. doi:10.1007/s00213-009-1521-8. PMC   2821721 . PMID   19337725.
  34. 1 2 Maitre M, Ratomponirina C, Gobaille S, Hodé Y, Hechler V (April 1994). "Displacement of [3H] gamma-hydroxybutyrate binding by benzamide neuroleptics and prochlorperazine but not by other antipsychotics". European Journal of Pharmacology. 256 (2): 211–214. doi:10.1016/0014-2999(94)90248-8. PMID   7914168.
  35. ↑ Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. (January 1997). "Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity". The Journal of Pharmacology and Experimental Therapeutics. 280 (1): 83–97. PMID   8996185.
  36. ↑ Blomme A, Conraux L, Poirier P, Olivier A, Koenig JJ, Sevrin M, Durant F, George P (2000). "Amisulpride, Sultopride and Sulpiride: Comparison of Conformational and Physico-Chemical Properties". Molecular Modeling and Prediction of Bioactivity. Springer US. pp. 404–405. doi:10.1007/978-1-4615-4141-7_97. ISBN   978-1-4613-6857-1.
  37. 1 2 Hopkins SC, Wilkinson S, Corriveau TJ, Nishikawa H, Nakamichi K, Loebel A, Koblan KS (September 2021). "Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5-HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders". Clinical Pharmacology and Therapeutics. 110 (3): 808–815. doi: 10.1002/cpt.2282 . PMC   8453756 . PMID   33961287.
  38. ↑ Grattan V, Vaino AR, Prensky Z, Hixon MS (August 2019). "Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7". ACS Omega. 4 (9): 14151–14154. doi:10.1021/acsomega.9b02144. PMC   6714530 . PMID   31497735.
  39. ↑ "SEP 4199". AdisInsight. Springer Nature Switzerland AG.
  40. ↑ Jethwa KD (2015). "Pharmacological management of antipsychotic-induced akathisia: An update and treatment algorithm". BJPsych Advances. 21 (5): 342–344. doi: 10.1192/apt.bp.114.013797 . S2CID   146670706.
  41. ↑ "Amisulpride international". Drugs.com. 3 February 2020. Retrieved 26 February 2020.
  42. 1 2 "Active substance: amisulpride" (PDF). 28 September 2017. EMA/658194/2017; Procedure no.: PSUSA/00000167/201701. Archived from the original (PDF) on 15 June 2018. Retrieved 26 February 2020.
  43. ↑ Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lempérière T, et al. (2001). "Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia". Neuropsychobiology. 44 (1): 41–46. doi:10.1159/000054913. PMID   11408792. S2CID   21103201.
  44. ↑ Kaplan A (2004). "Psychotropic Medications Around the World". Psychiatric Times. 21 (5).
  45. ↑ "Barhemsys: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 26 February 2020.
  46. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "Drug Trials Snapshots: Barhemsys". U.S. Food and Drug Administration (FDA). 26 February 2020. Retrieved 27 March 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  47. ↑ "Investor Presentation" (PDF). LB Pharmaceuticals. December 2022.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.